Clinical data mining reveals analgesic effects of lapatinib in cancer patients
Abstract Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs. Lapatinib, an FDA-approved drug for cancer treatment, has rece...
Guardado en:
Autores principales: | Shuo Zhou, Fang Zheng, Chang-Guo Zhan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c08fbabe69a47deb6bc50024576c91f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
por: J Robert McCorkle, et al.
Publicado: (2021) -
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
por: Geneviève Deblois, et al.
Publicado: (2016) -
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012) -
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011) -
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
por: Machado M, et al.
Publicado: (2012)